Clinical Trial Update: Safety and Efficacy of BAF312 in Dermatomyositis [Phase 2]

View source ↗

Summary

Phase 2 trial of BAF312 in active dermatomyositis was terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis

Drugs mentioned

• BAF312 (siponimod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Active Dermatomyositis | Phase 2 | Status: TERMINATED | Results posted: 2019-01-15